Over 3 million Aetna Medicare Advantage plan members nationwide will have access to Durolane, a single-injection hyaluronic acid-based joint-fluid treatment for patients with knee osteoarthritis pain.
Durolane is now one of two single-injection HA products under contract, according to a Dec. 6 press release from Bioventus.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.